Consistent with this mechanism, endothelial-targeted Lrrc8a ablation in vivo predisposes to microvascular dysfunction in the setting of T2D and to hypertension in response to Ang II infusion. The gene discussed is LRRC8A; the disease is type 2 diabetes mellitus.